Results of IFM 2014-01 Study (IxPd) From EHA 2022 | Int Myeloma Fn
Elotuzumab (Empliciti) Drug Info
Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma | Haematologica
Pharmaceuticals | Free Full-Text | Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
3791-Pomalidomide bortezomib and dexamethasone relapsed | eviQ
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial - The
Pomalidomide with dexamethasone direct anti-myeloma effects under... | Download Scientific Diagram
![PDF] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c2d9ab11b5739b401b8d3d2d135f5d895e4a8519/14-Figure3-1.png "PDF] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. | Semantic Scholar")
PDF] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. | Semantic Scholar
Multiple Myeloma Support + Trials
POMALYST® (pomalidomide) Treatment Option
Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis - Clinical Lymphoma, Myeloma and Leukemia
Hematology Reports | Free Full-Text | Efficacy of Bendamustine, Pomalidomide, and Dexamethasone (BPD) Regimen in Relapsed/Refractory Extramedullary Myeloma: A Retrospective Single-Centre Study, Real-Life Experience
Phase II Trials of Pomalidomide and Dexamethasone in Combination with Either Cyclophosphamide or Bortezomib in Relapsed or Refractory MM | Research To Practice
EMN11 - European Myeloma Network
OPTIMISMM Trial - Slideset Download - Clin Onc June 2018 | CCO
APOLLO trial results: Addition of daratumumab to pomalidomide + dexamethasone in relapsed/refractory multiple myeloma
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial - The Lancet Haematology
Pomalidomide/Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma | Research To Practice
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial | Blood Cancer Journal
Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma | Research To Practice
Daratumumab regimen extends PFS among certain patients with relapsed or refractory myeloma
